Breast Neoplasms Clinical Trial
Official title:
Phase 0 Trial of [F-18]-5-Fluoro-2'-Deoxycytidine With Tetrahydrouridine
Background:
- The drugs FdCyd (also called 5-fluoro-2'-deoxycytidine) and THU (also called
tetrahydrouridine) are being used in a cancer treatment study. Not a lot is known about how
FdCyd works in the body. Researchers want to look at a modified form of FdCyd using imaging
studies to see how the drug reacts with the cancer. This study is not a treatment study. It
is open only to people who are already on the FdCyd and THU cancer treatment study.
Objectives:
- To study how FdCyd affects advanced cancer cells.
Eligibility:
- Participants in National Cancer Institute study 09-C-0214.
Design:
- Participants will have two imaging studies, one before starting FdCyd and THU treatment
and one after starting treatment.
- Participants will have the modified FdCyd, known as F-18 FdCyd, with a dose of THU. The
doses will be followed by two imaging study scans and frequent blood samples.
- This procedure will be repeated at a later date, during the FdCyd and THU treatment
period.
- Treatment will not be provided as part of this study. This is an imaging study protocol
only....
BACKGROUND:
- In pre-clinical models, 5-fluoro-2-deoxycytidine (FdCyd), administered along with
tetrahydrouridine (THU; an inhibitor of cytidine/deoxycytidine deaminase), has shown superior
anti-tumor activity as compared with 5-fluorouracil.
- FdCyd can be phosphorylated to 5-fluoro-2-deoxycytidylate (FdCMP) by deoxycytidine
kinase and the nucleotide deaminated to FdUMP by deoxycytidylate (dCMP) deaminase.
The activity of dCMP deaminase is reported to be higher in human malignancies than in normal
tissues, which may result in selective cytotoxicity.
- FdCyd is an inhibitor of deoxyribonucleic acid (DNA) methyltransferase and DNA
methylation, resulting in reexpression of genes silenced by DNA hypermethylation. It is
being evaluated in a phase II multihistology clinical trial at the Developmental
Therapeutics Clinic, National Cancer Institute (NCI), Clinical Center, National
Institutes of Health (NIH).
- While FdCyd + THU has shown preliminary evidence of activity in early phase trials not
all patients show clinical response. The establishment of a radiolabeled form to image
the biodistribution in vivo at baseline and during therapy may provide insight into the
distribution of the therapeutic drug.
- The first step in the development of such an in vivo marker is to determine the
biodistribution and safety of the radiolabeled form.
OBJECTIVES:
- Determine the safety of [F-18]-5-fluoro-2'-deoxycytidine (FdCyd) administered
intravenously with administration of tetrahydrouridine (THU).
- Estimate the radiation dosimetry of [F-18]-FdCyd in humans.
ELIGIBILITY:
- Only patients enrolled in NCI Phase II Study evaluating FdCyd with THU (NCI Protocol #
09-C-0214 (CTEP# 8351) or NCI Protocol #12-C-0066 (CTEP# 9127)) at the NIH Clinical
Center will be eligible to participate in this study).
- Patients must have a target lesion greater than or equal to 10mm
- May not be pregnant or lactating; must be less than or equal to 350 lbs; and may not
have known allergy to FdCyd or contraindications to positron emission tomography
(PET)/computed tomography (CT) imaging.
DESIGN:
- There are two arms to this study
- The first arm will be patients enrolling in the therapeutic Phase II 5-FdCyd/THU study
(NCI Protocol # 09-C-0214 (CTEP# 8351) in the NCI Developmental Therapeutics Clinic
- The second arm will be patients enrolling in the Phase I 5-FdCyd/THU study (NCI Protocol
#12-C-0066 (CTEP# 9127)) in the NCI Developmental Therapeutics Clinic.
- Patients will undergo an initial [F-18]-FdCyd + THU PET/CT imaging prior to therapeutic
dosing on study NCI Protocol # 09-C-0214 (CTEP# 8351) or NCI Protocol #12-C-0066 (CTEP#
9127). Repeat imaging will be performed while the patient is receiving FdCyd + THU
therapy under the parent therapeutic protocol. This imaging must be completed 2-5 days
after cycle start and at least 2 hours after a dose. Upon completion of repeat imaging,
patients will be taken off this imaging study 24 hours after the last imaging session.
;
Status | Clinical Trial | Phase | |
---|---|---|---|
Enrolling by invitation |
NCT05558917 -
Comparison Between PECS BLOCK 2 vs ESP BLOCK in Ocnologic Breast Surgery
|
N/A | |
Active, not recruiting |
NCT03664778 -
Abbreviated Breast MRI After Cancer Treatment
|
||
Recruiting |
NCT03144622 -
18F-FSPG PET/CT Imaging in Patients With Cancers
|
||
Completed |
NCT05452499 -
Pain Neuroscience Education and Therapeutic Exercise as a Treatment for Breast Cancer Survivors Living With Sequelae
|
N/A | |
Active, not recruiting |
NCT04568902 -
Study of H3B-6545 in Japanese Women With Estrogen Receptor (ER)-Positive, Human Epidermal Growth Factor Receptor 2 (HER2)-Negative Breast Cancer
|
Phase 1 | |
Completed |
NCT02860585 -
Evaluation of Survival in Patients With Metastatic Breast Cancer Receiving High-dose Chemotherapy With Autologous Haematopoietic Stem Cell Transplantation
|
N/A | |
Completed |
NCT04059809 -
Photobiomodulation for Breast Cancer Radiodermatitis
|
Phase 2/Phase 3 | |
Recruiting |
NCT04557449 -
Study to Test the Safety and Tolerability of PF-07220060 in Participants With Advance Solid Tumors
|
Phase 1/Phase 2 | |
Completed |
NCT03698942 -
Delphinus SoftVueâ„¢ ROC Reader Study
|
||
Completed |
NCT00092950 -
Exercise in Women at Risk for Breast Cancer
|
Phase 2 | |
Terminated |
NCT04123704 -
Sitravatinib in Metastatic Breast Cancer
|
Phase 2 | |
Not yet recruiting |
NCT02151071 -
The Breast Surgery EnLight and LightPath Imaging System Study
|
Phase 1/Phase 2 | |
Recruiting |
NCT02934360 -
TR(ACE) Assay Clinical Specimen Study
|
N/A | |
Active, not recruiting |
NCT02950064 -
A Study to Determine the Safety of BTP-114 for Treatment in Patients With Advanced Solid Tumors With BRCA Mutations
|
Phase 1 | |
Not yet recruiting |
NCT02876848 -
A Novel E-Health Approach in Optimizing Treatment for Seniors (OPTIMUM Study)
|
N/A | |
Completed |
NCT02931552 -
Nuevo Amanecer II: Translating a Stress Management Program for Latinas
|
N/A | |
Recruiting |
NCT02547545 -
Breast Cancer Chemotherapy Risk Prediction Mathematical Model
|
N/A | |
Completed |
NCT02652975 -
Anticancer Treatment of Breast Cancer Related to Cardiotoxicity and Dysfunctional Endothelium
|
N/A | |
Completed |
NCT02303366 -
Pilot Study of Stereotactic Ablation for Oligometastatic Breast Neoplasia in Combination With the Anti-PD-1 Antibody MK-3475
|
Phase 1 | |
Completed |
NCT02518477 -
Preventive Intervention Against Lymphedema After Breast Cancer Surgery
|
N/A |